Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Recombinant Human EPO on Outcome of Encephalopathy Patients
IRCT2013033011470N2Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of erythropoietin in hypoxic-ischemic encephalopathy (HIE), sponsored by Shahrekord University of Medical Sciences. Started May 2013; status: completed.
02
Drugs
erythropoietin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on IRCT2013033011470N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013033011470N2.